METHODS: A total of 33 patients undergoing treatment or in post-treatment follow-up for medication-related osteonecrosis of the jaw, who visited our hospital between July 2020 and August 2021 and could receive SPECT twice on the same day, were enrolled in the study. Patients were injected with technetium-99 m hydroxymethylene diphosphonate (Tc-99 m HMDP) intravenously. The SUVmax for healthy parietal bones and jawbone lesions were calculated from the SPECT images using quantitative analysis software, and the SUVmax were compared between 2- and 3-hour uptake times.
RESULTS: After exclusion, 30 patients were included in the study. In the 2-hour and 3-hour images, the median SUVmax of the parietal bones were 1.90 and 1.81, respectively, and those of the jawbone lesions were 9.25 and 9.39, respectively. The limits of agreement (LOA) ranged from - 0.33 to 0.25 in the parietal bones, and the %LOA ranged from - 9.8 to 17.3% in the jawbone lesions, showing high equivalence between the two uptake durations. The SUVmax showed no clinical differences between the 2- and 3-hour uptake durations for Tc-99 m HMDP SPECT of the jawbone.
CONCLUSIONS: The results of this study justify a 2-3-hour uptake window when performing quantitative SPECT of the jawbone. Therefore, the minimum uptake time can potentially be reduced to only 2 hours.
方法:共33例患者因药物相关性颌骨坏死而接受治疗或治疗后随访,他在2020年7月至2021年8月期间访问了我们的医院,可以在同一天接受两次SPECT检查,参加了这项研究。患者静脉注射99m羟基亚甲基二膦酸盐(Tc-99mHMDP)。使用定量分析软件从SPECT图像计算健康顶骨和颌骨病变的SUVmax,和SUVmax在2和3小时摄取时间之间进行比较。
结果:排除后,30名患者被纳入研究。在2小时和3小时的图像中,顶骨的SUVmax中位数分别为1.90和1.81,颌骨病变分别为9.25和9.39。顶骨的一致性极限(LOA)范围为-0.33至0.25,下颌骨病变的%LOA范围为-9.8至17.3%,显示两个摄取持续时间之间的高度等效性。对于Tc-99mHMDPSPECT,SUVmax在2小时和3小时的摄取持续时间之间没有临床差异。
结论:在对颌骨进行定量SPECT时,这项研究的结果证明了2-3小时的摄取窗口。因此,最小摄取时间可以潜在地减少到仅2小时。